目的:建立一种高通量、快速检测拉夫米定耐药突变的新方法,指导临床抗病毒治疗药物的选择。方法:选取150例慢性乙型肝炎患者血清标本为研究对象,乙型肝炎病毒(Hepatitis B virus,HBV)DNA定量结果均阳性(拷贝数≥103拷贝/ml),设计针对聚...目的:建立一种高通量、快速检测拉夫米定耐药突变的新方法,指导临床抗病毒治疗药物的选择。方法:选取150例慢性乙型肝炎患者血清标本为研究对象,乙型肝炎病毒(Hepatitis B virus,HBV)DNA定量结果均阳性(拷贝数≥103拷贝/ml),设计针对聚合酶P区的扩增引物,经PCR扩增及磁珠分离,制备焦磷酸测序单链模板,并在PyroMark ID遗传分析系统上进行焦磷酸测序,检测拉夫米定耐药突变位点。结果:PCR扩增得到HBV P区产物,焦磷酸测序检测突变频率具有极高的灵敏性、特异性、稳定性的高通量的特征且与拉夫米定用药时间存在相关性。用药时间越长,突变率越高,易出现耐药。结论:新型、高通量焦磷酸测序法用于拉米夫定耐药突变检测,能满足临床批量用药检测及治疗方案设计的需要。展开更多
Objective To study the effect of fluvastatin on changes of serum C-reactive protein(CRP) and soluable intercellular adhesion molecule-1(sICAM-1),soluabe vas-cular cell adhesion molecule-1(sVCAM-1) contents in patients...Objective To study the effect of fluvastatin on changes of serum C-reactive protein(CRP) and soluable intercellular adhesion molecule-1(sICAM-1),soluabe vas-cular cell adhesion molecule-1(sVCAM-1) contents in patients with acute coronary syndrome(ACS). Methods 109 patients with ACS were randomly divided into fluvastatin-treated group(55 cases) and conventional therapy group (54 cases). The contents of serum CRP (with immunoturbidity method), sICAM-1,sVCAM-1 (with ELISA) were measured both before and after treatment for 8 weeks with fluvastat in in these cardiac patients as well as in 50 controls. Results ① Befor treatment, the levels of serum CRP, sICAM-1, sVCAM-1 were significantly higher in the patients with ACS than controls(P<0.01). ②After treatment,the levels of serum CRP, sICAM-1,sVCAM-1 in patients with fluvastatin decreased significantly(P<0.01), but the levels were not much changed in the conventional therapy group. Conclusion Fluvastatin can decrease inflammation and cell adhesion in patients with ACS .展开更多
文摘目的:建立一种高通量、快速检测拉夫米定耐药突变的新方法,指导临床抗病毒治疗药物的选择。方法:选取150例慢性乙型肝炎患者血清标本为研究对象,乙型肝炎病毒(Hepatitis B virus,HBV)DNA定量结果均阳性(拷贝数≥103拷贝/ml),设计针对聚合酶P区的扩增引物,经PCR扩增及磁珠分离,制备焦磷酸测序单链模板,并在PyroMark ID遗传分析系统上进行焦磷酸测序,检测拉夫米定耐药突变位点。结果:PCR扩增得到HBV P区产物,焦磷酸测序检测突变频率具有极高的灵敏性、特异性、稳定性的高通量的特征且与拉夫米定用药时间存在相关性。用药时间越长,突变率越高,易出现耐药。结论:新型、高通量焦磷酸测序法用于拉米夫定耐药突变检测,能满足临床批量用药检测及治疗方案设计的需要。
文摘Objective To study the effect of fluvastatin on changes of serum C-reactive protein(CRP) and soluable intercellular adhesion molecule-1(sICAM-1),soluabe vas-cular cell adhesion molecule-1(sVCAM-1) contents in patients with acute coronary syndrome(ACS). Methods 109 patients with ACS were randomly divided into fluvastatin-treated group(55 cases) and conventional therapy group (54 cases). The contents of serum CRP (with immunoturbidity method), sICAM-1,sVCAM-1 (with ELISA) were measured both before and after treatment for 8 weeks with fluvastat in in these cardiac patients as well as in 50 controls. Results ① Befor treatment, the levels of serum CRP, sICAM-1, sVCAM-1 were significantly higher in the patients with ACS than controls(P<0.01). ②After treatment,the levels of serum CRP, sICAM-1,sVCAM-1 in patients with fluvastatin decreased significantly(P<0.01), but the levels were not much changed in the conventional therapy group. Conclusion Fluvastatin can decrease inflammation and cell adhesion in patients with ACS .
